The global image-guided therapy systems market size was valued at USD 4.6 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030. The rise in the geriatric population and shifting preference for minimally invasive surgeries, along with technological advancements in imaging systems, are the key factors driving the market. The increased burden of chronic diseases, such as cancer coupled with a rise in the number of initiatives for cancer radiotherapy, is also positively impacting the market growth. For instance, according to international agency on cancer for research, in 2020 there were about 19,292,789 new cancer cases globally.
The market players are focused on developing remote solutions, such as cloud-based training on virtual machines, amid the COVID crisis to provide remote guidance and support to the patients. In November 2020, Royal Philips partnered with LeQuest to enable healthcare providers to gain online training for the Philips Ultrasound Affiniti system. Postponing non-urgent surgical procedures has negatively impacted image-guided therapy procedures.
According to the United Nations-World Population Prospects, 2019, about 16% of the global population or one in six people will be aged above 65 by 2050, up from 9% in 2019. According to the WHO, the global cause of death is shifting from infections to chronic conditions, including high cholesterol, hypertension, cancer, and cognitive heart diseases. Thus, the demand for image-guided therapy systems for treating these conditions is expected to rise in the coming years.
The growing preference for minimally invasive therapies is also propelling market growth. According to the national survey study conducted by Johns Hopkins Medicine, the use of minimally invasive surgeries for certain common procedures can reduce postoperative complications and can also control healthcare costs. Thus, the demand for minimally invasive image-guided therapies is projected to rise, thereby driving the market.
According to the Institute of Cancer Research, more than 120,000 people in the U.K. are treated with radiotherapy annually. Image-guided therapy systems have significantly improved, resulting in more precise and safer interventions. For instance, in December 2020, GE Healthcare launched Allia IGS 7 angiography system. The system was anticipated to help improve user experience, enhance workflow efficiency, and facilitate adoption of advanced image guidance in routine practice.
Various initiatives undertaken to promote cancer radiotherapy and increasing investments by private companies to develop advanced image-guided therapy systems are also contributing to market growth. Cancer Research U.K., Medical Research Council, and National Institute for Health Research are a few of the organizations active in cancer radiotherapy research. For instance, research is being conducted at the Department of Radiation Oncology, Stanford Medicine, for developing advanced cancer imaging, diagnostic, and minimally invasive treatment platforms.
The endoscopes segment accounted for the largest share of 32.3% in 2022. Increased adoption of robot-assisted endoscopic surgeries and the high cost of the systems are the key factors behind its largest revenue share. The high volume of endoscope-guided surgeries for various interventions has also contributed to its expansion. The growing incidences of cancer and gastrointestinal diseases have increased the demand for interventional endoscopic systems, thereby driving the segment.
This segment is also projected to expand at the fastest CAGR during the forecast period owing to technological advancements in endoscopy and subsequent product launches. In November 2017, Apollo Endosurgery received FDA approval for its endoscopic suturing system, OverStitch Sx, for soft tissue approximation and endoscopic placement of sutures.
Magnetic Resonance Imaging (MRI)-guided therapy system is the second-largest product segment with promising growth opportunities. Technological advancements and the wide application range of these therapies in treatment planning, localization and delivery, and treatment response assessment are the key factors responsible for the segment growth. These systems have major applications in areas, such as radiation oncology, neurology, and trauma care. Thus, the rising burden of such diseases is expected to boost product demand further.
The hospitals segment is expected to account for the largest revenue share of 37.0% in 2022. The increased number of various surgeries and high adoption of image-guided therapy systems in the hospitals are the primary factors driving the segment. Hospitals are adopting these systems owing to the increasing need for cost-effectively optimizing clinical workflows.
The ambulatory surgery centers (ASCs) segment is anticipated to exhibit the fastest CAGR over the forecast period. This growth is attributed to the advantages offered by these healthcare settings such as reduced waiting time and significant cost savings. High preference for minimally invasive surgeries and reduced hospital stays in the ASCs are also driving the segment. The growing trend of same-day surgery in developed economies due to significant cost savings and optimum care delivery also contributes to the segment growth.
Specialty clinics and research and academic institutions are other end-use segments. Increasing collaborations among research institutes and manufacturers, along with favorable initiatives for cancer treatment, are driving the research and academic institutions segment.
The cardiac surgery segment accounted for the largest share of 31.1% in 2022. Cardiovascular diseases (CVDs) are the leading cause of death globally. The rise in the geriatric population, coupled with the increasing burden of such diseases, is the major factor contributing to the segment growth. Various research initiatives undertaken for the development of real-time cardiac interventions are also positively impacting the segment growth.
The neurosurgery segment is likely to expand at a lucrative CAGR of 6.1% over the forecast period. The growing incidences of accidents and trauma cases and the high prevalence of neurological disorders are the major factors driving this segment. Increasing collaborations among key companies for developing new image-guided therapy systems are also fueling the segment growth.
The urology segment accounted for the second-largest revenue share in 2022. Image-guided therapy systems for urological applications are primarily used for diagnosis, treatment planning, and treatment assessment. Increasing research for the development of innovative systems using 3D and 4D imaging, robot-assisted image-guided therapies, and molecular imaging is expected to drive the segment.
North America captured the largest share of 36.4% in 2022 and is expected to maintain its lead over the forecast period. Improved healthcare infrastructure, technological advancements, and quick adoption of advanced radiation therapies are the factors fueling the growth of this market. The growing geriatric population base, coupled with the rising cases of chronic diseases, is also contributing to the regional market growth. The U.S. emerged as the largest market in North America in 2022 and accounted for 85.6% share. Favorable initiatives undertaken by private companies in the field of minimally invasive interventional and surgical techniques are expected to boost market expansion in the coming years.
Asia Pacific is projected to exhibit the fastest CAGR over the forecast period. The growing geriatric population, increasing cases of target diseases, and improving healthcare infrastructure are the factors responsible for its rapid growth. An increasing number of research centers in countries, such as India and China, are positively affecting the regional market growth.
The market is consolidated with the presence of Koninklijke Philips N.V., Siemens Healthineers, GE Healthcare, and Fujifilm Holdings Corporation accounting for the majority of the market share. Product launches, strategic acquisitions, and innovation are the major strategies adopted by the players to retain their market share.
In December 2020, Royal Philips announced collaboration with InSightec to develop MR-guided focused ultrasound that would help in non-invasive neurosurgery.
In September 2020, Philips announced the launch of its next generation image-guided therapy platform- Philips Azurion. The platform enables clinicians to handle multiple tasks with the help of single touch screen. Some prominent players in the global image-guided therapy systems market include:
Koninklijke Philips N.V.
Medtronic
Siemens Healthineers
Analogic Corporation
GE Healthcare
Varian Medical Systems, Inc.
Brainlab AG
Olympus Corporation
Stryker
Report Attribute |
Details |
Market size value in 2023 |
USD 4.8 billion |
Revenue forecast in 2030 |
USD 6.9 billion |
Growth rate |
CAGR of 5.2% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Sweden; Denmark; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key Companies profiled |
Koninklijke Philips N.V.; Medtronic; Siemens Healthineers; Analogic Corporation; GE Healthcare; Varian Medical Systems, Inc.; Brainlab AG; Olympus Corporation; Stryker |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels as well as provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global image-guided therapy systems market report based on product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Computed Tomography (CT) Scanners
Ultrasound Systems
Magnetic Resonance Imaging (MRI)
Endoscopes
X-ray Fluoroscopy
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Application Outlook (Revenue, USD Million, 2018 - 2030)
Cardiac Surgery
Neurosurgery
Orthopedic Surgery
Urology
Oncology Surgery
Gastroenterology
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Research & Academic Institutions
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global image-guided therapy systems market size was estimated at USD 4.6 billion in 2022 and is expected to reach USD 4.8 billion in 2023.
b. The global image-guided therapy systems market is expected to grow at a compound annual growth rate of 5.2% from 2023 to 2030 to reach USD 6.9 billion by 2030.
b. North America dominated the image-guided therapy systems market with a share of 36.37% in 2022. This is attributable to improved healthcare infrastructure, technological advancements, and quick adoption of advanced radiation therapies.
b. Some key players operating in the image-guided therapy systems market include Koninklijke Philips N.V., Siemens Healthineers, GE Healthcare, and Fujifilm Holdings Corporation.
b. Key factors that are driving the image-guided therapy systems market growth include a rise in the geriatric population and an increase in the burden of chronic diseases, an increase in the number of initiatives for cancer radiotherapy, technological advancements, and an increase in preference for minimally invasive surgeries.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."